MMP-12-M (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human macrophage metalloelastase (MMP-12, UniProt P39900) produced in HEK293 cells. Suitable for elastolytic activity assays, inhibitor IC50 determination, and antibody validation.
Expression system
HEK293
Cat. #
REC-MMP12M

In stock

SKU
REC-MMP12M
$498.00

Target Overview

MMP-12-M is recombinant human Matrix metalloproteinase-12 (Macrophage metalloelastase; UniProt P39900), produced by transient expression in HEK293 cells. The full-length MMP12 coding sequence spans 470 amino acids; depending on the expressed construct, the catalytic domain and/or propeptide may be present — consult the certificate of analysis for exact sequence boundaries and activation state. HEK293 expression provides mammalian glycosylation and folding, which is particularly relevant for MMPs whose activity and stability can be sensitive to post-translational modifications. MMP-12 is a secreted zinc-dependent endopeptidase of the metzincin superfamily. It exhibits pronounced elastolytic activity, cleaving elastin and a broad range of extracellular matrix (ECM) substrates. Its substrate preference has been characterised at the P1 and P1′ positions: aromatic or hydrophobic residues are favoured at P1, while leucine is preferred at P1′, with small hydrophobic residues (notably alanine) tolerated at P3. In the laboratory, this recombinant is used primarily in three contexts. First, for enzymatic activity assays — including fluorogenic peptide substrate cleavage (e.g., Mca/Dnp-based FRET substrates) and gelatin/elastin zymography — to characterise catalytic parameters (Km, kcat, kcat/Km) under defined conditions. Second, for inhibitor profiling and IC50 determination against small-molecule or peptide-based MMP-12 inhibitors. Third, as a positive-control antigen for antibody validation by Western blot and immunoassay; researchers requiring this application can pair MMP-12-M with Triple Point Biologics' matched anti-MMP-12 antibody (catalog no. RP-MMP12M), which has been validated for Western blot.

Background

Matrix metalloproteinase-12 (MMP-12), commonly designated macrophage metalloelastase or macrophage elastase, is a member of the MMP family of secreted, zinc-dependent endopeptidases. It is expressed predominantly by tissue macrophages and plays an established role in ECM remodelling through potent elastolytic activity. Beyond elastin, published substrates include fibronectin, vitronectin, laminin, type IV collagen, and plasminogen — the latter cleavage generating angiostatin, a finding that has drawn interest in tumour microenvironment research. MMP-12 has been studied extensively as a research target in chronic inflammatory and fibrotic conditions. In pulmonary biology, Mmp12-knockout mouse studies have been central to understanding the contribution of macrophage-derived elastase to smoke-induced emphysema and airway remodelling. The enzyme's role in macrophage-mediated ECM turnover has also been characterised in atherosclerotic plaque biology, where MMP-12 expression correlates with plaque vulnerability in human tissue studies. More recently, proteomic and epidemiological approaches have expanded the contexts in which MMP-12 is measured as a circulating biomarker. Huang et al. (2026) applied machine learning to UK Biobank plasma proteomics data — including MMP-12 — to examine protein associations with coronary artery disease risk, illustrating the enzyme's appearance in large-scale cardiovascular proteomic screens (PMID 42294785). Separately, MMP-12 has appeared in plasma proteomics panels investigating stroke and HIV-associated cerebrovascular disease (PMID 42265127), pancreatic cancer immune marker studies (PMID 42334072), and preterm labour inflammatory signatures (PMID 42327783), reflecting its broad utility as a quantifiable analyte in disease-associated inflammation research. At the bench, MMP-12 activity has been linked mechanistically to macrophage migration through basement membranes, a process relevant to in vitro invasion assays. Its preference for leucine at P1′ and hydrophobic residues at P1 has been exploited in the design of selective fluorogenic substrates and peptide-hydroxamate inhibitors, making recombinant MMP-12 a standard counterscreening reagent in MMP selectivity panels. Researchers designing selectivity assays across the MMP family typically include MMP-12 alongside MMP-2, -9, and -13 to establish inhibitor specificity profiles. Triple Point Biologics has been producing proteinase and inhibitor reagents since 1994. This recombinant is produced in HEK293 for compatibility with downstream mammalian-context assays where bacterial or insect-cell expression artefacts are a concern.

Applications

  • Fluorogenic peptide substrate (Mca/Dnp FRET) cleavage activity assay to determine Km and kcat
  • Elastin or gelatin degradation assay to confirm elastolytic activity
  • Inhibitor IC50 determination in MMP-12 selectivity counterscreens
  • MMP family selectivity panel — parallel profiling against MMP-2, MMP-9, MMP-13
  • Antibody validation positive control for Western blot paired with RP-MMP12M anti-MMP-12 antibody
  • Substrate identification by mass spectrometry using defined recombinant substrate
  • SPR or ITC-based biophysical binding characterisation of small-molecule or peptide inhibitors
  • Zymographic detection of MMP-12 activity in gelatin polyacrylamide gels

References

  1. Katzke VA et al. Immune Markers and Risk of Pancreatic Cancer in the European EPIC Cohort. Int J Cancer. 2026. doi:10.1002/ijc.70581. PMID: 42334072.
  2. Hong S et al. Vaginal dysbiosis and inflammatory signatures in preterm labor: an integrated model for predicting preterm birth. Front Immunol. 2026. doi:10.3389/fimmu.2026.1809046. PMID: 42327783.
  3. Huang Y et al. Machine Learning-Driven Prediction of Coronary Artery Disease Risk Based on UK Biobank Plasma Proteomics. J Am Heart Assoc. 2026. doi:10.1161/JAHA.125.047248. PMID: 42294785.
  4. Chen T et al. Targeted plasma proteomics reveals a central role of upregulated TNFRSF proteins in HIV-associated stroke. Nat Commun. 2026. doi:10.1038/s41467-026-74258-8. PMID: 42265127.
  5. Cong L et al. Causal effects of mental disorders on stroke subtypes: A proteome-wide Mendelian randomization and mediation analysis. Medicine (Baltimore). 2026. doi:10.1097/MD.0000000000049108. PMID: 42260810.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What molecular weight band should I expect for MMP-12-M (Recombinant) on SDS-PAGE or Western blot?

Full-length human MMP-12 (470 aa) has a predicted molecular weight of ~54 kDa, but the expressed construct in REC-MMP12M is produced in HEK293 cells and may represent the catalytic domain and/or propeptide region rather than the full-length protein — check your certificate of analysis for exact sequence boundaries. Mammalian glycosylation from HEK293 expression typically shifts the apparent MW 2–5 kDa above the calculated value on reducing SDS-PAGE. Confirm activation state (pro vs. active form) before interpreting band position; the active catalytic domain runs closer to ~40 kDa.

What processing forms or isoforms of MMP-12 does this recombinant represent, and is it in active or zymogen form?

MMP-12 is synthesized as a ~54 kDa zymogen (including signal peptide and propeptide) and processed to an active ~45 kDa form upon propeptide removal, with further C-terminal truncation yielding an active ~22 kDa catalytic domain. REC-MMP12M is produced by transient HEK293 expression; the exact construct boundaries and activation state — whether zymogen, propeptide-removed active enzyme, or isolated catalytic domain — are specified on the certificate of analysis. If your downstream assay requires fully active enzyme, verify activation status before use and do not assume activity without confirming the construct form.

What substrates does recombinant MMP-12 cleave and what is its substrate preference for activity assays?

MMP-12 is a broad-spectrum elastolytic endopeptidase. It cleaves elastin, gelatin, fibronectin, vitronectin, and several collagens. At the scissile bond, MMP-12 favours aromatic or bulky hydrophobic residues (e.g., Tyr, Phe, Leu) at P1 and leucine at P1′, with small hydrophobics such as alanine tolerated at P1′ as well. For fluorogenic activity assays, FRET-based substrates such as Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 or the generic MMP substrate Mca-PLGL-Dpa-AR are widely used and compatible with REC-MMP12M. Confirm substrate concentration and Km in your specific buffer conditions before calculating specific activity.

What buffer conditions should I use for recombinant MMP-12-M activity assays and does glycerol interfere?

REC-MMP12M is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2. The CaCl2 is essential for MMP catalytic domain stability and must be maintained in your assay buffer at 1–5 mM. For fluorogenic assays, dilute into a working buffer of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 0.05% Brij-35 — the detergent prevents surface adsorption at low enzyme concentrations. Glycerol carried over from storage is generally tolerable at <1% final concentration but can quench some fluorophores; keep dilution factor ≥10× when possible.

What starting concentration of recombinant MMP-12 should I use for a fluorogenic activity assay IC50 experiment?

For IC50 determinations against small-molecule or protein inhibitors, a practical starting point is 1–5 nM REC-MMP12M with a fluorogenic substrate (e.g., Mca-PLGL-Dpa-AR) at 10–20 µM (~1× Km). Using enzyme at or below Km allows accurate Ki estimation via the Cheng-Prusoff equation. At concentrations above 10 nM, tight-binding inhibitors (e.g., TIMP-1/TIMP-2) will show stoichiometric rather than hyperbolic inhibition curves, complicating IC50 fits. Always pre-incubate enzyme with inhibitor for 15–30 min at room temperature before adding substrate to allow equilibrium binding.

Can I use MMP-12-M (Recombinant) as a positive control for Western blot with the matched rabbit polyclonal antibody RP-MMP12M?

Yes — REC-MMP12M and antibody RP-MMP12M (see /anti-mmp-12m-rabbit-polyclonal-antibody) are developed in the same laboratory and validated as a matched pair for Western blot positive controls. Loading 20–50 ng of REC-MMP12M per lane on a standard 10–12% SDS-PAGE gel gives a clear, clean band with RP-MMP12M at the expected apparent MW under reducing conditions. This combination is also suitable for validating RP-MMP12M against endogenous MMP-12 in macrophage lysates (e.g., LPS/IFN-γ stimulated THP-1 or primary BMDM), where the recombinant serves as a size and signal reference.

How much recombinant MMP-12-M should I load as a Western blot positive control alongside cell lysate samples?

Load 20–50 ng of REC-MMP12M per lane alongside your cell or tissue lysates. At 20 ng, RP-MMP12M (used at a typical 1:1000–1:2000 dilution) produces a readily detectable band without overwhelming the ECL signal or bleeding into adjacent lanes. If your lysate samples are run at 20–40 µg total protein, a 25 ng recombinant lane provides a proportionate signal reference. Because MMP-12 is a secreted enzyme, include conditioned media concentrate controls where relevant — the recombinant lane confirms antibody and transfer efficiency independently of intracellular expression levels.

How should I store and handle REC-MMP12M to preserve activity after arrival, and what is its shelf life?

Upon receipt, centrifuge briefly and store REC-MMP12M at -20°C in single-use aliquots — the 10% glycerol in the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2) provides cryoprotection. Avoid repeated freeze-thaw cycles; each cycle can measurably reduce specific activity of zinc-dependent endopeptidases. Aliquot to working volumes (typically 5–10 µL) at first thaw. When diluting for assays, use a carrier buffer containing 0.1% BSA to prevent adsorptive losses at concentrations below 10 nM. Stored correctly, activity is stable for ≥12 months at -20°C. Do not store at 4°C long-term.

Validation imagery coming soon

Western blot validation figures for REC-MMP12M will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →